BGI Genomics: Revenue in 2025 is expected to be 3.6-3.9 billion, with a net loss estimated at 530-630 million.

Huada Genetics announced that the expected operating income for 2025 is 3.6-3.9 billion yuan, with a change of -6.90% to 0.86% compared to the same period last year; the net profit attributable to the shareholders of the listed company is -0.53- -0.63 billion yuan, a loss of 0.903 billion yuan from the same period last year. The main reasons for the performance change are fluctuations in market demand, intensified industry competition, and a decrease in gross profit margins for some products. The company has actively adjusted its business structure, with different performances in various business sectors. In addition, the extended customer repayment cycle has led to an increase in credit impairment losses, and impairment provisions have been set aside for some delivery center strategic adjustments, although expenses have been effectively controlled. Non-recurring gains and losses are expected to have an impact of approximately 15-45 million yuan.